pril-changed PA does not have a direct relationship to the hypotensive mechanism of this drug. The inversely proportional changes in PA suggest several interesting hypotheses not only for elucidation of the hypotensive mechanism of captopril but also for investigation of the basic structure of hypertension. However, it is necessary first to clarify the mechanism underlying the present results.
The factors related to the regulation of PA include ACTH, the metabolic clearance rate of aldosterone (MCR), potassium balance and A II. The plasma ACTH was not determined in the present study but PC was essentially unchanged at each dose of captopril. An effect on the anterior pituitary cannot therefore be adduced to explain the complex changes in PA observed in the present study.
The possibility of changes in MCR requires careful consideration.
The MCR of aldosterone was closely related with hepatic blood flow which was lower in an upright posture than a supine posture (Culbertson et al., 1951) , and under A II infusion (Messerli et al., 1977) . A captopril-induced increase in MCR was described by Honda et al. (1982) . In this report, 25mg of the drug was administered to patients with hypertension. The increase in MCR following captopril administration might be partially helpful in the reduction of PA. Since MCR is influenced by the plasma A II level, the value of MCR should be increased following captopril administration in a dose dependent manner. It is difficult therefore to explain the mechanism of the inconsistentlooking changes in PA observed in the present study on the basis of MCR. The other factor which is known to play an important role in the regulation of aldosterone is the potassium balance (Bartter, 1956; Brunner et al., 1970) . In our previous study, potassium loading significantly increased PA with a significant elevation of the serum potassium level (Ueda et al., 1982) . However, there were no significant changes in the serum potassium level after the administration of 25mg of captopril in the present study. The possibility of a potassiuminduced change in PA can thus be excluded.
Another important factor which is changed after captopril administration is kinin. The role of captopril-increased kinin in the hypotensive action of the drug has been demonstrated in several reports (McCaa et al., 1978; Carretero et al., 1980) . On the other hand, Eguchi et al. (1980) found that exogenously administered bradykinin enhanced PA in animal experiments. It is worthy of consideration therefore that captopril-enhanced kinin could influence the PA reduction which results from a decrease in A II. The correlation between the degree of increase in plasma kinin and that of captopril may be direct, so that the elevated kinin after administration of 25mg of the drug could be stronger in inhibiting the PA reduction than that after 5mg or 12.5mg of the drug. A low dose of captopril might not have the ability to lower blood pressure and to elevate endogenous kinin. However, this dose should be sufficient for an A II-mediated fall in PA. On the other hand, 25mg of captopril could lower blood pressure through a multiple action, due to a decrease in A II and an increase in kinin. Based on the above hypothesis explaining the mechanism underlying the present results, it is considered that excess kinin elevated by 25mg of captopril could interrupt the reduction in PA. In addition, Hulthen and Hokfelt (1978) indicated that a higher dose of SQ 20,881 is required to inhibit kinin degradation than to inhibit angiotension conversion. This was related to the report that purified converting enzyme from human lung has a specific activity for bradykinin which is 14times higher than that for angiotensin I (Nishimura et al., 1977) . Thus, 5mg of captopril might act only in the conversion of angiotension I, and 25mg of the drug could exert a multiple action inhibiting both the conversion of angiotension I and the degradation of kinin. However, although the present study supports the interaction of kinin and aldosterone, it does not prove it.
Another way to explain the present results is the role of a dopaminergic mechanism in controling aldosterone secretion. Edwards et al. (1975) suggested the dopaminergic inhibition of aldosterone production, and this proposition has been supported by several investigators (McKenna et al., 1979 , Carey et al., 1979 , Noth et al., 1980 . If changes in dopamine mediated a curious alteration in PA in the present study, it should be considered that captopril might suppress the dopaminergic activity in a dose dependent manner. In this theory, 25mg of captopril might be a dose adequate to decrease the dopaminergic suppression of PA while 5mg of the drug might be insufficient to do so. However, the role of dopamine under captopril administration is not clear, and the above mentioned possibility is too slight to discuss now.
We looked at possible explanations for a novel effect of captopril on PA, and because these were all constituted from indirect evidence, further studies on this problem will be required.
